SHIONOGI

Chemoinformatics	● High-accuracy, high-speed virtual screening technologies for large-scale virtual libraries ● Technology for high-precision docking (SBDD) and simulation (LBDD) of peptide therapeutics ● Molecular generation methods for efficiently generating drug-like molecules
Small Molecules Targeting RNA	● Method for measuring the binding affinity of RNA-targeting small molecules with in vivo relevance ● Excludes SPR, ITC, MST, AS-MS and SHAPE ● High through put in silico screening technology for RNA ● Efficient method for evaluating the three-dimensional structure of RNA
Drug discovery method aimed at covalent binders	● Fundamental technologies ● Evaluation methods for drug discovery
Screening and Synthesis Automation Technologies	● Operate throughout the day
Protein Production	● Technology employing DNA vectors to substantially accelerate protein production, applicable to E. coli as well as mammalian and other animal cell systems. ● In silico methods for accurately designing mass-enhancing proteins to facilitate Cryo-EM structural determination

SHIONOGI

Peptide Therapeutics	● Identification of targets suitable for peptide drug discovery, including undruggable targets such as protein–protein interactions ● Synthesis technologies aimed at reducing manufacturing costs of peptide therapeutics ● Formulation technology for efficient oral or nasal absorption of peptide drugs (e.g. solubilized formulations)
Nucleic Acid Therapeutics	● Neurodegenerative diseases and motor dysfunction diseases for siRNA therapeutics ● Technology for long-term refrigerated storage of mRNA-LNP formulations ● Informatics-driven optimization of LNP formulation (delivery efficiency, safety, stability, and tissue selectivity) ● Technology to enhance mRNA expression efficiency ● Technology for circularizing mRNA
Antibody Therapeutics	● Technology to deliver antibodies into brain ● Discovery of novel target molecules for antibody drug development - Chronic infectious diseases - Central nervous system diseases - Motor dysfunction diseases

Pharmacokinetics	● In vitro assay for predicting human biliary clearance and enterohepatic circulation ● Drug transport and drug-drug interaction (DDI) risk prediction models using human P-gp/BCRP transgenic or knock-in animals ● Intracellular drug quantification for PK/PD and MoA insights ● Predict the risk of P-gp or BCRP inhibitory effects on drug absorption and disposition
Safety	● AI system to classify biochemical toxicity data as adverse or non-adverse ● In silico toxicity mechanism analysis system ● Predicting toxicity target organs using live animal image diagnosis (CT, MRI, etc.) ● In vitro model for ocular toxicity evaluation and mechanism analysis ● In vitro evaluation system to evaluate damage and regeneration of inner ear hair cells ● In vivo evaluation system for ototoxicity using ABR (Auditory Brainstem Response) ● Ames avoidance measures and prediction tools in nucleic acid analog drug discovery
Drug Discovery Platform Technologies	● Method for screening and optimizing enzyme activity based on substrate specificity of metabolite biosynthetic enzymes ● Bioinformatics techniques including enzyme sequence data ● Data-driven optimization for reproducible scale-up cultivation